MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, GALT had -$2,246K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$2,246K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-8,184 -17,152
Stock-based compensation expense
496 968
Amortization of right to use lease asset
0 12
Non-cash interest expense
215 696
Change in fair value of derivative liabilities
2,205 1,121
Prepaid expenses and other assets
-467 -428
Accounts payable, accrued expenses and other liabilities
-345 -3,239
Accrued interest on convertible debt - related party
1,604 2,875
Net cash from operating activities
-3,542 -14,291
Net proceeds from exercise of common stock options and warrants
443 724
Net proceeds from issuance of common stock
853 1,218
Net proceeds from convertible line of credit related party
0 11,000
Net cash flows from financing activities
1,296 12,942
Net (decrease)/increase in cash and cash equivalents
-2,246 -1,349
Cash and cash equivalents at beginning of period
15,120 -
Cash and cash equivalents at end of period
11,525 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

GALECTIN THERAPEUTICS INC (GALT)

GALECTIN THERAPEUTICS INC (GALT)